RET and non-small cell lung carcinoma: Additionally, the LIBRETTO-431 (NCT04194944) and ARROW (NCT03037385) trials, while primarily focused on treatment-naïve RET fusion-positive NSCLC, may yield insights relevant to the acquired resistance setting (20, 21).